Literature DB >> 18519401

Current treatment standards and future strategies in mantle cell lymphoma.

M Dreyling1, O Weigert, W Hiddemann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519401     DOI: 10.1093/annonc/mdn193

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.

Authors:  Christian Bogner; Tobias Dechow; Ingo Ringshausen; Michaela Wagner; Madlen Oelsner; Gloria Lutzny; Thomas Licht; Christian Peschel; Ira Pastan; Robert J Kreitman; Thomas Decker
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

2.  Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.

Authors:  Jorge Gayoso Cruz; Rodrigo Martino; Pascual Balsalobre; Inmaculada Heras; José Luis Piñana; David Serrano; Javier de la Serna; José Francisco Tomás; Joséa Luis Díez-Martíin; Dolores Caballero
Journal:  Ther Adv Hematol       Date:  2011-02

3.  Mantle cell lymphoma of the larynx: Primary case report.

Authors:  Sarah Naciri; Anass A Bennani-Baiti; Meriem Glaoui; Houda Mouzount; Samia Ghanem; Leila Essakali; Mohamed Kzadri; Hassan Errihani
Journal:  J Med Case Rep       Date:  2012-07-16

4.  Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound.

Authors:  Timur Saliev; Loreto B Feril; Koichi Ogawa; Akiko Watanabe; Dinara Begimbetova; Askhat Molkenov; Dauren Alimbetov; Katsuro Tachibana
Journal:  Med Sci Monit       Date:  2016-12-22

5.  Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Authors:  David Chiron; Peter Martin; Maurizio Di Liberto; Xiangao Huang; Scott Ely; Brian J Lannutti; John P Leonard; Christopher E Mason; Selina Chen-Kiang
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.